{"entity":{"id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","aka":[],"tldr":"A phase 3 trial of Sintilimab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting.","summary":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer is a phase 3 interventional study registered as NCT05890742 by Innovent Biologics (Suzhou) Co. Ltd., with 453 participants enrolled, started 2023-05-25 and due to reach its primary completion in 2028-04-15. Interventions recorded: Sintilimab, IBI310&Sintilimab and Radical surgery.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05890742","url":"https://clinicaltrials.gov/study/NCT05890742"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05890742","phase":"3","setting":"A Phase 1b/3 Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":453,"outcomes":[]},"route":"/trials/nct05890742/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}]}}